Brainsway ( (BWAY) ) has released its Q1 earnings. Here is a breakdown of the information Brainsway presented to its investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
BrainsWay Ltd. is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, utilizing its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology. In the first quarter of 2025, BrainsWay achieved record quarterly sales of $11.5 million, marking a 27% increase compared to the same period in 2024. The company also reported a significant rise in operating profit and adjusted EBITDA, with increases of 519% and 81%, respectively. BrainsWay shipped a record number of Deep TMS systems, reflecting strong demand and strengthening relationships with enterprise accounts. The company’s net profit saw a substantial increase of 897% to $1.1 million. BrainsWay continues to make progress in clinical trials for major depressive disorder and post-traumatic stress disorder, and it maintains its full-year financial guidance with expected revenues between $49 million to $51 million. Looking forward, BrainsWay’s management anticipates continued growth driven by its next-generation Deep TMS 360 system, expansion into new indications, and enhanced global market presence.